Innate Pharma: positive data in lymphoma

(CercleFinance.com) - At the ASH annual meeting in San Diego (December 7-10), Innate Pharma announces new positive data from the TELLOMAK Phase II clinical trial evaluating lacutamab in advanced cutaneous T-cell lymphomas.


Patients, particularly those with Sézary syndrome and mycosis fungoides, often present distressing symptoms such as severe itching and recurrent skin infections, and therefore report a lower quality of life.

"The results highlight promising early signs that lacutamab could help alleviate some of the most distressing symptoms of cutaneous T-cell lymphomas", reports the pharmaceutical company.

Copyright (c) 2024 CercleFinance.com. All rights reserved.